Your browser doesn't support javascript.
loading
Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control.
Inzucchi, Silvio E; Kosiborod, Mikhail; Fitchett, David; Wanner, Christoph; Hehnke, Uwe; Kaspers, Stefan; George, Jyothis T; Zinman, Bernard.
Affiliation
  • Inzucchi SE; Section of Endocrinology, Yale University School of Medicine, New Haven, CT (S.E.I.).
  • Kosiborod M; Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City (M.K.).
  • Fitchett D; St Michael's Hospital, Division of Cardiology, University of Toronto, Canada (D.F.).
  • Wanner C; Department of Medicine, Würzburg University Clinic, Germany (C.W.).
  • Hehnke U; Boehringer Ingelheim International GmbH, Germany (U.K., S.K., J.T.G.).
  • Kaspers S; Boehringer Ingelheim International GmbH, Germany (U.K., S.K., J.T.G.).
  • George JT; Boehringer Ingelheim International GmbH, Germany (U.K., S.K., J.T.G.).
  • Zinman B; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Ontario, Canada (B.Z.).
Circulation ; 138(17): 1904-1907, 2018 10 23.
Article in En | MEDLINE | ID: mdl-30354665
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Benzhydryl Compounds / Blood Glucose / Cardiovascular Diseases / Diabetes Mellitus, Type 2 / Sodium-Glucose Transporter 2 Inhibitors / Glucosides Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Year: 2018 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Benzhydryl Compounds / Blood Glucose / Cardiovascular Diseases / Diabetes Mellitus, Type 2 / Sodium-Glucose Transporter 2 Inhibitors / Glucosides Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Year: 2018 Type: Article